Antigen specific memory T cells and their putative need for the generation of sustained anti-tumor responses

Advances in Experimental Medicine and Biology

Volumn 684, Issue , 2010, Pages 155-165

  Alderson, Kory L ^b   Murphy, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD28 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; L SELECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA VACCINE; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG POTENTIATION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MEMORY T LYMPHOCYTE; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T CELL DEPLETION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION; UPREGULATION; ANIMAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASM; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 77956843084     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6451-9_12     Document Type: Review

References (64)

1. Weinberg RA. The Biology of Cancer 1st ed. New York: Garland Science, Taylor and Francis Group; 2007
2. Minev BR, Chavez FL, Mitchell MS. Cancer vaccines: Novel approaches and new promise. Pharmacol Ther 1999; 81:121-139 (Pubitemid 29073560)
3. Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine 2007; 25 (Suppl 2) B72-88
4. Govan VA. A novel vaccine for cervical cancer: Quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil). Ther Clin Risk Manag 2008; 4:65-70 (Pubitemid 351460931)
5. Muderspach L, Wilczynski S, Roman L et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000; 6:3406-3416
6. Poolman EM, Elbasha EH, Galvani AP. Vaccination and the evolutionary ecology of human papillomavirus. Vaccine 2008; 26 Suppl 3:C25-30 (Pubitemid 351910687)
7. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225-274 (Pubitemid 40563170)
8. Sheu BC, Lin RH, Lien HC et al. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 2001; 167:2972-2978
9. Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg Oncol Clin N Am 2007; 16:755-774, viii (Pubitemid 350101281)
10. Gajewski TF. Failure at the effector phase: Immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007; 13:5256-5261 (Pubitemid 47510348)
11. Simpson-Abelson M, Bankert RB. Targeting the TCR signaling checkpoint: A therapeutic strategy to reactivate memory T-cells in the tumor microenvironment. Expert Opin Ther Targets 2008; 12:477-490 (Pubitemid 351546372)
12. Porta C, Subhra Kumar B, Larghi P et al. Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol 2007; 604:67-86
13. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8:467-477 (Pubitemid 351733418)
14. Koyama S, Koike N, Adachi S. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: A possible mechanism of immune evasion of the tumor. J Cancer Res Clin Oncol 2002; 128:73-79 (Pubitemid 34117828)
15. Lopez-Gonzalez JS, Hernandez Garcia A, Noyola MI et al. Evasion mechanisms to tumor necrosis factor alpha (TNF-alpha) of small cell lung carcinoma and nonsmall cell lung carcinoma cell lines: Comparison with the erythroleukaemia K-562 cell line. Lung Cancer 2000; 27:177-187 (Pubitemid 30105657)
16. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008; 68:2561-2563 (Pubitemid 351556251)
17. Savage PA, Vosseller K, Kang C et al. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T-lymphocytes. Science 2008; 319:215-220
18. Eerola AK, Soini Y, Paakko P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 2000; 6:1875-1881 (Pubitemid 30305084)
19. Parshad R, Hazrah P, Kumar S et al. Effect of preoperative short course famotidine on TILs and survival in breast cancer. Indian J Cancer 2005; 42:185-190 (Pubitemid 43479199)
20. Liakou CI, Narayanan S, Ng Tang D et al. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun 2007; 7:10
21. Ohtani H. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 2007; 7:4
22. Dunn GP, Dunn IF, Curry WT. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 2007; 7:12
23. Holmes EC. Immunology of tumor infiltrating lymphocytes. Ann Surg 1985; 201:158-163 (Pubitemid 15170080)
24. Blohm U, Roth E, Brommer K et al. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes. J Immunol 2002; 169:5522-5530 (Pubitemid 35291650)
25. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-854 (Pubitemid 35231542)
26. Koebel CM, Vermi W, Swann JB et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903-907 (Pubitemid 350231320)
27. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22:329-360 (Pubitemid 38680426)
28. Berner V, Liu H, Zhou Q et al. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med 2007; 13:354-360 (Pubitemid 46376686)
29. Zhang B, Bowerman NA, Salama JK et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T-cells. J Exp Med 2007; 204:49-55 (Pubitemid 46148755)
30. Zhang B, Zhang Y, Bowerman NA et al. Equilibrium between host and cancer caused by effector T-cells killing tumor stroma. Cancer Res 2008; 68:1563-1571 (Pubitemid 351346866)
31. Kumar R, Burns EA. Age-related decline in immunity: Implications for vaccine responsiveness. Expert Rev Vaccines 2008; 7:467-479 (Pubitemid 351681640)
32. Chambers SM, Goodell MA. Hematopoietic stem cell aging: Wrinkles in stem cell potential. Stem Cell Rev 2007; 3:201-211 (Pubitemid 350129706)
33. Aw D, Silva AB, Palmer DB. Immunosenescence: Emerging challenges for an ageing population. Immunology 2007; 120:435-446 (Pubitemid 46365019)
34. Pugliese A. Central and peripheral autoantigen presentation in immune tolerance. Immunology 2004; 111:138-146 (Pubitemid 38177942)
35. Keir ME, Liang SC, Guleria I et al. Tissue expression of PD-L1 mediates peripheral T-cell tolerance. J Exp Med 2006; 203:883-895
36. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-1034
37. Goldberg MV, Maris CH, Hipkiss EL et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T-cells. Blood 2007; 110:186-192 (Pubitemid 47026834)
38. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002; 8:793-800
39. Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994; 12:991-1045
40. Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T-cell responses to vaccination with peptide, IFA and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115:739-746 (Pubitemid 40322250)
41. Anderson TD, Hayes TJ, Powers GD et al. Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals. Int Rev Exp Pathol 1993; 34 Pt A:57-77
42. Dutcher J, Atkins MB, Margolin K et al. Kidney cancer: The Cytokine Working Group experience (1986-2001): Part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol 2001; 18:209-219 (Pubitemid 33097348)
43. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-327 (Pubitemid 28144091)
44. Escobar A, Lopez M, Serrano A et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 2005; 142:555-568 (Pubitemid 41719853)
45. Harthun NL, Weaver AM, Brinckerhoff LH et al. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2. J Immunother 1998; 21:85-94 (Pubitemid 28141712)
46. Roberts JD, Niedzwiecki D, Carson WE et al. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother 2006; 29:95-101
47. Lindsey KR, Gritz L, Sherry R et al. Evaluation of prime/boost regimens using recombinant poxvirus/ tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin Cancer Res 2006; 12:2526-2537
48. Sallusto F, Lanzavecchia A. Exploring pathways for memory T-cell generation. J Clin Invest 2001; 108:805-806 (Pubitemid 32880290)
49. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T-cell subsets: Function, generation and maintenance. Annu Rev Immunol 2004; 22:745-763 (Pubitemid 38680440)
50. Sprent J, Surh CD. T-cell memory. Annu Rev Immunol 2002; 20:551-579
51. Surh CD, Boyman O, Purton JF et al. Homeostasis of memory T-cells. Immunol Rev 2006; 211:154-163
52. Suresh M, Whitmire JK, Harrington LE et al. Role of CD28-B7 interactions in generation and maintenance of CD8 T-cell memory. J Immunol 2001; 167:5565-5573 (Pubitemid 33062745)
53. Vallejo AN. CD28 extinction in human T-cells: Altered functions and the program of T-cell senescence. Immunol Rev 2005; 205:158-169 (Pubitemid 40780184)
54. Perez-Diez A, Joncker NT, Choi K et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109:5346-5354 (Pubitemid 46890556)
55. Badovinac VP, Messingham KA, Griffith TS et al. TRAIL deficiency delays, but does not prevent, erosion in the quality of "helpless" memory CD8 T-cells. J Immunol 2006; 177:999-1006 (Pubitemid 44036602)
56. Sun JC, Williams MA, Bevan MJ. CD4+ T-cells are required for the maintenance, not programming, of memory CD8+ T-cells after acute infection. Nat Immunol 2004; 5:927-933 (Pubitemid 39276237)
57. Prlic M, Williams MA, Bevan MJ. Requirements for CD8 T-cell priming, memory generation and maintenance. Curr Opin Immunol 2007; 19:315-319 (Pubitemid 46687015)
58. Janssen EM, Droin NM, Lemmens EE et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005; 434:88-93 (Pubitemid 40349390)
59. Janssen EM, Lemmens EE, Wolfe T et al. CD4+ T-cells are required for secondary expansion and memory in CD8+ T-lymphocytes. Nature 2003; 421:852-856 (Pubitemid 36254145)
60. Alderson KL, Zhou Q, Berner V et al. Regulatory and conventional CD4+ T-Cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy. J Immunol 2008; 180:2981-2988
61. Murphy WJ, Welniak L, Back T et al. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: Coordination of dendritic and CD8+ cell responses. J Immunol 2003; 170:2727-2733 (Pubitemid 36245667)
62. Bartholdy C, Kauffmann SO, Christensen JP et al. Agonistic anti-CD40 antibody profoundly suppresses the immune response to infection with lymphocytic choriomeningitis virus. J Immunol 2007; 178:1662-1670 (Pubitemid 46154638)
63. Verneris MR, Karami M, Baker J et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T-cells. Blood 2004; 103:3065-3072 (Pubitemid 38451682)
64. Wen H, Dou Y, Hogaboam CM et al. Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response. Blood 2008; 111:1797-1804. (Pubitemid 351451484)